Cancer combo trial halted early: what we know
NCT ID NCT05221320
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tested two drugs—ulixertinib and hydroxychloroquine—in 47 people with advanced gastrointestinal cancers that have certain genetic mutations (MAPK pathway). The goal was to see if the combination could shrink tumors. However, the study was terminated early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ulixertinib and hydroxychloroquine
What this could lead to
If successful, this combination could offer a new treatment option for advanced gastrointestinal cancers with specific genetic mutations.
What could go wrong
The trial was terminated early, so we have limited data on effectiveness. It was also a small, early-phase study, so results may not apply broadly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Massey Cancer Center, Virginia Commonwealth University
Richmond, Virginia, 23298, United States
-
Mount Sinai
New York, New York, 10029, United States
-
Rogel Cancer Center, University of Michigan Health
Ann Arbor, Michigan, 48109, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University of Arizona Cancer Center
Tucson, Arizona, 85719, United States
-
University of California San Francisco
San Francisco, California, 94143, United States
-
University of Kansas Cancer Center
Fairway, Kansas, 66205, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States